Does Kaiser Permanente Cover Qsymia (Phentermine/Topiramate ER)?

Kaiser covers Qsymia only when your plan includes a weight-loss benefit and Qsymia is on Kaiser's closed-network weight-management formulary. Medi-Cal excluded all weight-loss drugs as of January 1, 2026, so California Medicaid members cannot access it. Standard Medicare Part D excludes it by statute. When excluded, the Qsymia Engage cash program (~$89/month) or the 2025 generic (~$63 with coupon) are the realistic options. Verify coverage on Kaiser's member formulary at kp.org.

Qsymia is REMS-restricted, meaning it can only be prescribed by REMS-enrolled physicians and dispensed at REMS-certified pharmacies. Your Kaiser physician must be enrolled in the Qsymia REMS program to prescribe it. If you are of reproductive potential, mandatory monthly pregnancy testing is required during treatment due to topiramate's teratogenic risk. Confirm with your Kaiser physician whether the REMS requirements can be met within Kaiser's system or through an external REMS-certified pharmacy.

No. Medi-Cal excluded all weight-loss drugs effective January 1, 2026. This applies to Kaiser Foundation Health Plan California Medicaid members. Qsymia cannot be covered through Kaiser Medi-Cal plans from 2026 onward. The Engage cash program (~$89/month) or the generic (~$63 with coupon) from an external REMS-certified pharmacy are the only routes for Medi-Cal members who want Qsymia.

Both Qsymia and phentermine face the same Kaiser hurdles: plan AOM benefit plus Kaiser's internal formulary, Medi-Cal exclusion from 2026, and Medicare Part D statutory exclusion. The critical difference is clinical: standalone phentermine is simpler (no REMS, no teratogenicity concern) and far cheaper at $10–$40 cash, but is FDA-approved for only about 12 weeks. Qsymia offers longer authorized use and greater efficacy through the topiramate combination, but requires REMS enrollment, pregnancy monitoring, and CV contraindication screening. Discuss with your Kaiser physician which approach fits your clinical situation.

All three exclude Qsymia under standard Medicare Part D by statute. Kaiser's distinguishing angle is its closed-network HMO formulary — you get Kaiser's weight-management list, and Medi-Cal is excluded from 2026. Humana's angle is Medicare-focused: Humana runs the GLP-1 Bridge but the Bridge does not cover oral AOMs like Qsymia. Anthem's angle is commercial employer-carve-out variability with an open formulary and a usable savings card for commercial members. For all three, the Engage program (~$89/month) or the 2025 generic (~$63) is the cash fallback.